Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Is neoadjuvant immunotherapy a therapeutic platform for all tumour types?

Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage?

Date

21 Oct 2023

Session

Is neoadjuvant immunotherapy a therapeutic platform for all tumour types?

Topics

Translational Research;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Tina Cascone

Authors

T. Cascone

Author affiliations

  • Thoracic Head And Neck Medical Oncology, The University of Texas MD Anderson Cancer Center - Main Building, 77030 - Houston/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and Discussion

Presenter: All Speakers

Session: Is neoadjuvant immunotherapy a therapeutic platform for all tumour types?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.